Traders should monitor FDA acceptance and review timeline under RTOR, upcoming medical conference data presentation, and potential near-term catalysts from AdvSM NDA submission expected in first half of 2026. Positive regulatory response could drive significant upside.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 1 $35.24entry
- T+1 · 8mo ago −0.09%α −0.16% · $35.21
- T+5 · 7mo ago +5.99%α +2.22% · $37.35
- T+20 · 7mo ago +1.79%α −7.93% · $35.87
- T+60 · 5mo ago +9.93%α −3.45% · $38.74
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Cogent Biosciences announced the submission of a New Drug Application (NDA) for bezuclastinib in second-line GIST under the FDA's RTOR program, based on positive Phase 3 PEAK trial results showing a 50% reduction in progression risk and 16.5-month median PFS. The drug combination also demonstrated a 46% objective response rate, significantly outperforming sunitinib monotherapy.
Key Facts
- Submitted NDA for bezuclastinib in imatinib-resistant GIST under FDA's Real-Time Oncology Review (RTOR) program
- Phase 3 PEAK trial showed 50% reduction in risk of progression or death (HR 0.50) vs sunitinib monotherapy
- Median PFS of 16.5 months with bezuclastinib combination vs 9.2 months for sunitinib alone
- Objective response rate (ORR) of 46% vs 26% in control arm
- Bezuclastinib previously granted Breakthrough Therapy Designation by FDA
- Full data to be presented at a major medical meeting in first half of 2026
- Company plans to initiate Phase 2 trial in first-line GIST patients with exon 9 mutations this quarter
Financial Impact
Potential blockbuster revenue if approved; no direct financial figures disclosed but clinical results support high commercial upside
Risk Factors
- FDA may not approve the NDA or may require additional data
- Immature overall survival data leaves long-term efficacy uncertain
- Recent insider selling of $242.6M in the past 30 days raises potential concern about confidence in near-term prospects
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3266534 |
Track record
13 reports on COGT
4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +17.43% at T+20 after the Jun 12, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $33.54 Now $27.44 −18.19% settles Feb 5
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $31.65 Now $27.44 −13.29% settles Feb 4
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
- Aug 10, 202614w ago Press Release Neutral 5/10 Entry $41.53 to $31.06 Now $27.44 −33.93% ▼ −25.21% −22.79% vs SPY
- Aug 9, 202614w ago Institutional Cluster Bullish 6/10 Entry $41.53 to $31.06 Now $27.44 −33.93% ▼ −25.21% −22.79% vs SPY
- Jun 12, 202622w ago Press Release Neutral 4/10 Entry $33.10 to $35.28 Now $27.44 −17.10% ▲ +6.59% +3.32% vs SPY
- Jun 12, 202622w ago Press Release Bullish 7/10 Entry $33.10 to $35.28 Now $27.44 −17.10% ▲ +6.59% +3.32% vs SPY
- May 30, 202624w ago Press Release Bullish 8/10 Entry $34.81 to $36.80 Now $27.44 −21.17% ▲ +5.72% +4.49% vs SPY
- May 28, 202624w ago Press Release Bullish 8/10 Entry $35.38 to $36.73 Now $27.44 −22.44% ▲ +3.82% +2.08% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers